TRIM22: A Diverse and Dynamic Antiviral Protein by Hattlmann, Clayton J. et al.
Hindawi Publishing Corporation
Molecular Biology International
Volume 2012, Article ID 153415, 10 pages
doi:10.1155/2012/153415
Review Article
TRIM22: A Diverse and Dynamic AntiviralProtein
ClaytonJ. Hattlmann,Jenna N.Kelly,andStephen D.Barr
Department of Microbiology and Immunology, Center for Human Immunology, The University of Western Ontario,
London, ON, Canada N6A 5C1
Correspondence should be addressed to Stephen D. Barr, stephen.barr@uwo.ca
Received 9 January 2012; Accepted 24 February 2012
Academic Editor: Abraham Brass
Copyright © 2012 Clayton J. Hattlmann et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The tripartite motif (TRIM) family of proteins is an evolutionarily ancient group of proteins with homologues identiﬁed in both
invertebrate and vertebrate species. Human TRIM22 is one such protein that has a dynamic evolutionary history that includes
gene expansion, gene loss, and strong signatures of positive selection. To date, TRIM22 has been shown to restrict the replication
of a number of viruses, including encephalomyocarditis virus (EMCV), hepatitis B virus (HBV), and human immunodeﬁciency
virus type 1 (HIV-1). In addition, TRIM22 has also been implicated in cellular diﬀerentiation and proliferation and may play a
role in certain cancers and autoimmune diseases. This comprehensive paper summarizes our current understanding of TRIM22
structure and function.
1.Introduction
The TRIM gene family encodes a diverse group of proteins
that are involved in many biological and antiviral processes.
There are currently 100 known TRIM genes in the human
genome and many of these genes are upregulated by
multiple, distinct stimuli [1–3]. Historically, TRIM genes
have been researched mainly for their antiviral properties;
however this paradigm is changing. Two recent reports
discussing the role of TRIM genes in autoimmunity and
cancer highlight the importance of the TRIM family in
the development of nonviral diseases [4, 5]. Many TRIM
genes also have a dynamic evolutionary history and the
TRIM family has been shown to undergo extensive gene
duplication in both primates and teleost ﬁsh [1, 6]. In
addition, several TRIM genes have experienced strong pos-
itive selection in primates [7]. Although the forces behind
TRIM evolution remain unclear, it is possible that the TRIM
family has evolved and continues to evolve, in response to
new viral pathogens or endogenous danger signals. This
paper provides an overview of the TRIM22 gene and
summarizesitsstructure,evolution,expression,andantiviral
activities.
2. Structure
TRIM proteins typically contain a conserved RBCC motif,
which consists of an amino-terminal RING domain, one
or two B-box domains, and a predicted coiled-coil region.
Approximately 60% of TRIM proteins, including TRIM22,
also contain a carboxyl-terminal domain B30.2 domain
(Figure 1)[ 8, 9]. The RING domain of TRIM22 has
homology with E3 ligases and has been shown to possess
E3 ubiquitin ligase activity [9, 10]. The catalytic cysteine
residues Cys15 and Cys18 are essential for this activity and
mediatethetransferofubiquitintotargetproteins (Figure 1)
[11, 12]. TRIM22 can also modify itself with ubiquitin which
leads to proteasomal degradation [10, 11]. Interestingly, the
TRIM family represents one of the largest groups of E3
ubiquitin ligases and E3 ligase activity seems to be crucial
for TRIM-mediated carcinogenesis [4]. In addition, E3 ligase
activity is important for many TRIM-mediated antiviral
activities and for TRIM22, it is required for the inhibition
o fE M C V ,H B V ,a n dH I V - 1[ 11, 13, 14].
TRIM proteins typically contain one or two B-box
domains, although B-box 1 is never present without B-box
2, and the two domains have diﬀerent consensus sequences2 Molecular Biology International
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Figure 1: Structure and variability of TRIM22 and TRIM5α protein domains. TRIM22 contains an amino-terminal RING domain, one
B-box domain (B-box 2), a coiled-coil region, and a carboxyl-terminal B30.2 domain (SP1 = Spacer 1 and SP2 = Spacer 2). Two cysteine
residues (Cys15 and Cys18) in the RING domain are required for the E3 ligase activity of TRIM22, and a number of positively selected
amino acids are found in the coiled-coil and B30.2 domains. The location and spacing of positively selected amino acids in TRIM22 are
similar to those found in TRIM5α, which may reﬂect species-speciﬁc pathogenic pressures. The approximate location of positively selected
amino acids in TRIM22 and TRIM5α is denoted with a star, and the location of the β2-β3 surface loop of TRIM22 is also indicated (arrows).
Single nucleotide polymorphisms (SNPs) in the coding regions of TRIM22 and TRIM5α are shown as vertical bars, along with the type
of mutation that each SNP can generate (green: nonsynonymous mutations; yellow: missense mutations; pink: frameshift mutations; red:
nonsense mutations).
[15, 16]. TRIM22 contains one B-box domain (B-box 2),
of which no clear function has been assigned (Figure 1).
Certain B-box 2 mutations have been shown to aﬀect viral
recognition by other TRIM proteins, such as TRIM5α.
S i m i l a rt oT R I M 2 2 ,T R I M 5 α has been shown to inhibit
HIV-1 replication albeit at an earlier stage in the viral
lifecycle. Interestingly, the human orthologue of TRIM5α
only modestly inhibits HIV-1 replication whereas the rhesus
orthologue of TRIM5α (rhTRIM5α) has potent anti-HIV-1
activity [17]. Several mechanisms of rhTRIM5α-mediated
HIV-1 inhibition have been proposed; however, the favoured
mechanism involves rhTRIM5α binding to the HIV-1 core
and disruption of the normal uncoating process (reviewed
in [18, 19]). For rhTRIM5α, the RING and B-box 2 domains
promote its dimerization and higher-order self-association
on the HIV-1 capsid [17]. It is unknown whether the
B-box 2 domain of TRIM22 is required for higher-order
self-association; however, it has been shown to play a role in
the nuclear localization of TRIM22 [20].
The coiled-coil domain contains multiple predicted
hypersecondary structures and intertwined α-helices [21]. In
TRIM proteins, the coiled-coil domain is thought to pro-
mote homo-oligomerization, as its deletion prevents TRIM
protein self-association [22]. Homo-oligomerization can be
important for the formation of higher-molecular-weight
complexes that deﬁne speciﬁc subcellular structures, such
as nuclear bodies [21, 22]. Although the role of the coiled-
coil region of TRIM22 remains unclear, self-association is a
function of the coiled-coil region in other TRIM proteins.
For example, the coiled-coil region of rhTRIM5α is required
for rhTRIM5α trimerization and may be involved in the
formation of cytoplasmic bodies. Importantly, rhTRIM5α
trimerizationisthoughttodriveitsinteractionwiththeHIV-
1capsidandthecoiled-coilregionisrequiredforrhTRIM5α-
mediated HIV-1 restriction [17, 23]. TRIM22 has also been
shown to form trimers and to restrict HIV-1 replication but
it is unknown whether the coiled-coil domain is required for
these processes [14, 22, 24–26].
The B30.2 domain of TRIM proteins consists of two
separate domains called the PRY and SPRY domains that
form a putative protein-protein interaction site [27, 28].
This interaction site is likely important for the antiviral
activities of TRIM22 and other TRIM proteins. Indeed, the
B30.2 domain of rhTRIM5α is required for trimerization
and HIV-1 restriction [23]. Three hyper-variable regions
in the B30.2 domain of rhTRIM5α are thought to form
the binding surface for the HIV-1 capsid protein [29].
In addition, these hypervariable regions confer the virus
speciﬁcity of rhTRIM5α. The B30.2 domain of TRIM22 also
contains these three hypervariable regions but their role
in HIV-1 restriction has not yet been established. Similar
to rhTRIM5α, the hypervariable regions in TRIM22 are
highly polymorphic and contain a large number of positively
selected amino acids (Figure 1)[ 7]. It will be interesting to
learn if the B30.2 domain of TRIM22 confers speciﬁcity for
targets such as viral pathogens. Notably, the B30.2 domain is
required for the formation of nuclear bodies [13, 20, 30].
3. Evolution of TRIM22
The human TRIM22 gene is located on chromosome 11,
immediately adjacent to the TRIM5, TRIM6, and TRIM34
genes [7, 31]. The origins of TRIM22, and the entire
TRIM5/6/22/34 gene cluster, can be traced back to the Creta-
ceous period, sometime after the divergence of Metatherian
(marsupial) and Eutherian (placental) mammals (Figure 2).
Previous studies have shown that the TRIM5/6/22/34 locus
is absent in Metatherian mammals such as opossum and
chicken but presents in the major Eutherian groups contain-
ing cow, dog, and human [7]. Thus, this gene cluster must
have emerged after the Metatherian-Eutherian division but
before the separation of the major Eutherian groups. Taken
together, this dates the birth of TRIM22 (along with TRIM5,
TRIM6 and TRIM34) to approximately 90–180 million years
ago (Figure 2)[ 7].
The TRIM5/6/22/34 gene cluster likely arose through
tandem gene duplication, as these four TRIM genes are close
human paralogs and because major gene rearrangements
have been documented in this chromosomal regionMolecular Biology International 3
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Figure 2: Timeline of Metatherian and Eutherian mammalian evolution showing the emergence of TRIM22. The divergence of Metatherian
(marsupial) and Eutherian (placental) mammals occurred approximately 180 million years ago in the Jurassic period of the Mesozoic
era. The TRIM22 gene emerged sometime after this division, as it is absent in Metatherian mammals but present in all major Eutherian
groups. In addition, since TRIM22 is present in all Eutherian mammals, it must have emerged before further Eutherian division occurred
(approximately 90 million years ago). Taken together, this dates the birth of TRIM22 to approximately 90–180 million years ago. The
predicted window of time for TRIM22 emergence in Eutherian mammals is demarcated with two red arrows. MYA: millions of years.
[1, 7, 32]. Gene duplication plays a major role in evolution
and TRIM genes have been shown to undergo extensive
gene duplication in both primates and teleost ﬁsh [1, 6].
One of the most important outcomes of gene duplication
is neofunctionalization, whereby one copy of the duplicate
gene acquires a novel, beneﬁcial function, and the other copy
of the gene retains its original function [33–35]. This type of
gene manipulation is a potent driver of evolution because it
allows an organism to create new, potentially advantageous
genes without disrupting the integrity of the original gene.
Recently, a genomic analysis of a diﬀerent branch of the
TRIM genefamilyidentiﬁedseveralTRIM genesonchromo-
some 11 that have given rise to multiple TRIM paralogs in
humans and African apes [1]. A group of 7 TRIM genes that
are present in all Eutherian mammals (TRIM43, TRIM48,
TRIM49, TRIM51, TRIM53, TRIM64, and TRIM77)w e r e
shown to spawn 11 new TRIM genes in certain primates and
6n e wTRIM genes in humans, primarily through segmental
duplications [1]. These new TRIM genes have presumably
evolved and adapted to react against more recently emerged
pathogenic threats. In addition, a Han Chinese woman with
12 new TRIM genes was identiﬁed, documenting for the
ﬁrst time TRIM gene copy number variation in humans
[1]. Given its role in antiviral immunity, TRIM22 probably
emerged in a similar manner as a means of counteracting
new viral pathogens; however the exact selective pressures
giving rise to the TRIM22 gene remain unclear.
According to a recent study, TRIM genes can be divided
into two main groups based on their structural similarities
and evolutionary properties [36]. Group 1 members have
two B-box domains, have variable C-terminal domains, and
are represented in both vertebrate and invertebrate species.
In contrast, Group 2 members have only one B-box domain
(B-box 2), are characterized by a C-terminal SPRY domain,
andarefoundonlyinvertebrates.Inaddition, Group2genes
are younger and smaller and evolve more rapidly than Group
1g e n e s[ 36]. Compared to some other TRIM genes, TRIM22
is young and has evolved under strong positive selection,
thus TRIM22 (along with the TRIM5/6/22/34 gene cluster)
is classiﬁed as a Group 2 gene. Interestingly, the authors
suggest that Group 2 genes may act as TRIM gene reservoirs,
spawning new genes to respond to species-speciﬁc changes
at the host-pathogen interface. Consistent with this inter-
pretation, there are a number of positively selected amino
acids in TRIM22 which all cluster at predicted virus inter-
action sites in the coiled-coil and B30.2 domains (Figure 1)
[7, 36].
Within the TRIM5/6/22/34 gene cluster, TRIM22 and
TRIM5 have a unique evolutionary relationship. In some
Eutherian groups, such as cow, there are multiple copies of
the TRIM5 gene and no TRIM22 gene. However in others
such as dog, the TRIM22 gene is present and the TRIM5
gene is absent [7]. In addition, the strong positive selection
that each of these two genes has experienced over millions
of years has occurred in a mutually exclusive manner. This
type of anticorrelative pattern is probably due to genetic
linkage between the two genes, whereby positive selection
of an advantageous mutation in one gene indirectly leads
to the selection of a linked mutation in the other [7].
The location and spacing of positively selected amino acids
in TRIM22 is very similar to those found in TRIM5α
(Figure 1). In both proteins, the positively selected amino
acids are located in the coiled-coil and B30.2 domains, which
is interesting because their amino acid sequences are actually
the least similar in these regions. The majority of positively
selected amino acids in TRIM22 are found within the β2-β3
surface loop of the B30.2 domain, an area that is important
for HIV-1 recognition in TRIM5α (Figure 1)[ 7, 37, 38].
It is possible that TRIM22 and TRIM5α once possessed a
similar antiretroviral mechanism, and that they evolved over
time to respond to species-speciﬁc pathogenic pressures.
Indeed, many studies have shown that rhesus TRIM5α,b u t
not human TRIM5α, can potently inhibit HIV-1 replication
[18, 39]. In contrast, human TRIM22 can inhibit HIV-1
replication and thus may have evolved to compensate for the
loss of TRIM5α’s anti-HIV function.
The TRIM22 gene has a dynamic evolutionary history
thatincludesgeneexpansion,geneloss,andstrongsignatures
of positive selection in primates [1, 6, 7, 36]. The high
number of nonsynonymous mutations found in TRIM22,
alongwithitsclassiﬁcationasaGroup2TRIM gene,suggests
that this gene continues to evolve at a rapid pace. Given the
volatile state of other TRIM genes in chromosome 11, it is
possible that the TRIM5/6/22/34 gene cluster takes part in4 Molecular Biology International
Table 1: Summary of the localization patterns observed for TRIM22.
Localization Pattern Cell Type Epitope Tag Reference
Cytoplasm
Diﬀuse
Diﬀuse
Diﬀuse
Diﬀuse with speckles/bodies
Diﬀuse
Diﬀuse
Diﬀuse with speckles/bodies
293T
COS7
HeLa
HeLa
HeLa
PBMCs
U2OS
GFP or V5/His
GFP or V5/His
Endogenous
GFP
GFP or V5/His
Endogenous
GFP
[40]
[40]
[40]
[22]
[40]
[40]
[22]
Cytoplasm & Nucleus
Nucleoplasmic, with nuclear bodies1
Diﬀuse throughout, or nuclear bodies2
Nucleoplasmic, with nuclear bodies
Diﬀuse, with cytoplasmic bodies3
Nucleoplasmic with NB4
Nucleoplasmic, with nuclear bodies
Nucleoplasmic and cytoplasmic
Diﬀuse with speckles5−7
ABC28
HeLa
HeLa
HeLa
MCF7
MCF7
T47D
U2OS
Endogenous
EGFP
Endogenous
FLAG
EGFP, EYFP, or FLAG
Endogenous
Endogenous
Endogenous
[30]
[30]
[30]
[43]
[30]
[30]
[30]
[42]
Nucleus
Aggregates/bodies
Aggregates/bodies
Diﬀuse with speckles/bodies
Diﬀuse with speckles/bodies
Diﬀuse with bodies
293
COS7
HepG2
HepG2
MCF7
Myc
Myc
Endogenous
Myc
FLAG
[41]
[10]
[13]
[13]
[20]
1Some colocalization with ﬁbrillarin (Nucleoli).
2Pattern changes with cell cycle phase: (G0/G1: nuclear bodies; S-phase: nuclear speckles and cytoplasmic; mitosis: diﬀuse throughout cell).
3TRIM22 plasmid was coexpressed with Rhesus TRIM5α.
4Partial colocalization with Cajal bodies.
5Potential colocalization with calnexin (Endoplasmic reticulum).
6Localization was primarily cytoplasmic when cells were ﬁxed with paraformaldehyde, or both cytoplasmic and nuclear when ﬁxed with ice-cold methanol.
7Partial colocalization with the centrosome.
gene and/or segmental duplication in humans. Presumably,
individuals with an increased number of these TRIM genes
may have an augmented antiviral response and could be
particularly adept at controlling retroviral infections. Similar
to copy number variations, a number of single nucleotide
polymorphisms (SNPs) exist in TRIM22 that may inﬂuence
its antiviral capacity or biological function for that matter.
Forinstance,therearetwodocumentedframeshiftmutations
and one documented nonsense mutation in the National
Center for Biotechnology Information SNP database for
the TRIM22 gene (Figure 1). If present, these SNPs would
generate diﬀerent truncated versions of the TRIM22 protein,
which may alter its structure, E3 ubiquitin ligase activity
and/or antiviral function. There are also twenty documented
missense mutations in the TRIM22 gene, the majority of
w h i c ha r ef o u n di ni t sB 3 0 . 2d o m a i n( Figure 1). Many of
these SNPs have the potential to impact TRIM22 function
and their presence or absence may contribute to individual
diﬀerences in TRIM22-mediated activities.
4.Biological FunctionsofTRIM22
4.1. TRIM22 Localization. There are several contradictory
reports detailing the subcellular localization of TRIM22.
Some reports have observed that TRIM22 localizes pre-
dominantly to the cytoplasm [22, 40] or to the nucleus
[10, 13, 20, 41], whereas other reports have observed that
TRIM22 can localize to both the cytoplasm and the nucleus
(Table 1)[ 30, 42, 43]. The pattern of localization also
varied between diﬀuse, speckled, and aggregated. A number
of explanations have been given in the literature for the
diﬀerences in localization, including whether the expression
was endogenous (e.g., IFN-treatment) or exogenous (e.g.,
overexpression). In addition, the method of ﬁxation and
the type of epitope tag used for detection have also been
reported to aﬀect the localization pattern. Given the diverse
range of cell lines used in these studies, it is also possible
that cell type-speciﬁc factors inﬂuence the localization of
TRIM22.
AnumberofdeterminantsaﬀectingTRIM22localization
have been identiﬁed. A bipartite nuclear localization signal
(NLS) located in the Spacer 2 domain of TRIM22 was shown
to be necessary, but not suﬃcient, for nuclear localization
[20]. Although there are no known NLSs present in the
B30.2/SPRY domain, several groups have shown that this
domain is required for nuclear localization [13, 20, 40, 41].
More speciﬁcally, Val 493 and Cys 494 of the B30.2 domain
were shown to be critical for nuclear localization and the
formation of nuclear bodies [20]. In an independent study,
amino acids Ser 395, Lys 396, and Ser 400 located in variable
loops 1 and 3 of the B30.2 domain were shown to be
important for certain localization patterns of TRIM22 [40].
In some cell types, TRIM22 localizes in the nucleus
as punctate bodies, which have been shown to partially
colocalizewithCajalbodies[20].Cajalbodiesplayimportant
roles in RNA processing and modiﬁcation as well as in cell
cycle progression [44]. TRIM22 also interacts with p80-
coilin, which is a major component of Cajal bodies. Similar
to Cajal bodies, TRIM22 localization has been shown to
change during the cell cycle. In G0/G1 TRIM22 localizesMolecular Biology International 5
in nuclear bodies, in S-phase it localizes in a more diﬀuse
and speckled pattern throughout the nucleus, and during
mitosis it assumes a diﬀuse pattern in both the nucleus
and cytoplasm [30]. In an independent study, TRIM22 was
shown to colocalize with the centrosome independently of
the cell cycle and also with vimentin-containing aggresome-
like structures next to the endoplasmic reticulum [42]. From
these data, it appears that multiple factors inﬂuence the
localization of TRIM22, possibly indicating that TRIM22 has
several biological roles.
4.2. Antiviral Function of TRIM22. Several reports including
published transcriptional proﬁling datasets (e.g., GDS1096,
GDS3113, and GDS596) deposited in the Gene Expression
Omnibus database repository (http://www.ncbi.nlm.nih.
gov/gds) show that TRIM22 is ubiquitously expressed in
several human tissues and is highly upregulated in response
to Type I and II interferons (Table 2)[ 7, 13, 14, 24, 25, 45–
50]. Interestingly, the 5  ﬂanking region of the TRIM22
gene contains two regions matching the consensus sequence
for an IFN-stimulating response element (ISRE) and a
third region matching that for an IFN-γ activation site
(GAS); however ISRE1 or GAS is not required for IFN-
γ induction of TRIM22. In contrast, the ISRE2 plus six
upstream nucleotides (extended ISRE) is capable of binding
IFN regulatory factor 1 (IRF1) in a manner dependent on
the chromatin remodelling enzyme Brahma-related gene 1
(BRG1) [48, 49]. Furthermore, this extended ISRE appears
to be important for both stimulation by IFN-α and IFN-γ
as well as for basal TRIM22 expression [48]. The signiﬁcant
upregulation of TRIM22 in response to IFNs, together with
the ﬁnding that TRIM22 has evolved under strong positive
selection for millions of years, suggests that TRIM22 plays an
important fundamental role in cell biology. To date, several
lines of evidence suggest that this role is as an antiviral factor.
Human TRIM22 was ﬁrst discovered by Tissot and
Mechti in 1995 during a search for IFN-induced genes
in Daudi cells, where exogenous expression of TRIM22
was shown to downregulate transcription from the HIV-1
LTR [45]. Although this was performed using a luciferase
reporter gene under the transcriptional control of the
HIV-1 LTR and not in the context of the entire HIV-1
proviral genome, it provided the ﬁrst evidence suggesting
that TRIM22 blocks HIV-1 transcription and replication.
In 2006, Bouazzaoui et al. showed that TRIM22 was highly
upregulated in primary monocyte-derived macrophages
(MDMs) in response to HIV-1 infection, IFNα treatment,
orstimulationwithlipopolysaccharide(LPS).Theyprovided
the ﬁrst evidence that TRIM22 can restrict HIV-1 replication
in vitro by showing that exogenous expression of TRIM22
inhibited HIV-1 infection by 50–90% in 293T cells modiﬁed
to express the CD4 and CCR5 receptors and in primary
MDM.Furthermore,cotransfectionofTRIM22withathree-
plasmid system for replication-defective HIV-1 resulted in
reduced infectious titres of pseudotyped virus, suggesting
that TRIM22 inhibited a late stage of HIV-1 pseudoparticle
production and/or subsequent infection with the pseudo-
typed virus [24].
In 2008, Barr et al. showed that TRIM22 was an
integral part of the Type I interferon-induced inhibition
of HIV-1 replication and provided the ﬁrst mechanistic
data for the inhibition of HIV-1 replication by TRIM22.
TRIM22 expression in several human cell lines potently
inhibited HIV-1 replication, and interestingly, analysis of
Gag production in those cells revealed that TRIM22 may
inhibit HIV-1 replication by two diﬀerent mechanisms. In
the HOS and HeLa cell lines, TRIM22 inhibited HIV-1
particle production by interfering with the traﬃcking of the
Gag polyprotein to the plasma membrane. Since TRIM22
and Gag proteins interact, and that the E3 ligase activity of
TRIM22 is required for this restriction [14], it is possible
that TRIM22 posttranslationally modiﬁes Gag, resulting in
altered Gag traﬃcking to the plasma membrane. In the
U2OS and 143B cell lines, TRIM22 inhibited HIV-1 particle
production by inhibiting the accumulation of intracellular
Gag protein [14]. Although no mechanism of restriction
was identiﬁed in U2OS or 143B cells, several possibilities
could explain the decrease in intracellular Gag protein
levels, including inhibition of transcription from the LTR as
previouslysuggested[25,45],ordegradationoftheGagRNA
and/or polyprotein. Given that TRIM22 exhibits cell type-
speciﬁc diﬀerences in localization (as discussed earlier), it
is likely that the mechanism of TRIM22-induced restriction
of HIV-1 particle production is cell type-speciﬁc and/or
dependent on the subcellular localization of TRIM22. Future
experiments are required to further elucidate the mechanism
of TRIM22-induced inhibition of HIV-1 particle production
(Figure 3).
TRIM22 was also independently identiﬁed and shown
to inhibit HIV-1 replication by several laboratories [25].
Following observations made by Franzoso et al. in 1994
that clones of the U937 promonocytic cell line were
either permissive or nonpermissive to HIV-1 replication,
Kajaste-Rudnitski et al. (2011) identiﬁed TRIM22 as the
only known restriction factor that was expressed in the
nonpermissive and absent from the permissive U937 cells.
Using a luciferase reporter plasmid under the control of the
HIV-1 LTR, they showed that LTR-mediated transcription
was decreased 7–10-fold in nonpermissive clones. They
also showed that by knocking down TRIM22 expression in
nonpermissive cells, the levels of transcription from the LTR
approached those observed in permissive cells. Exogenous
expression of TRIM22 in permissive clones also decreased
LTR transcription to levels comparable to those observed
in nonpermissive clones. Further investigation revealed that
TRIM22 inhibited basal and phorbol myristate acetate-
ionomycin-induced HIV-1 transcription. These eﬀects were
independent of NFκB, HIV-1 Tat and the E3 ubiquitin ligase
activityofTRIM22[25].It is important to note that alldirect
evidence showing that TRIM22 inhibits HIV-1 transcription
has been through the use of LTR-driven reporter constructs.
It will be important to test the eﬀects of TRIM22 on HIV-1
LTR transcription in the context of full-length replication-
competent HIV-1.
In 2011, Singh et al. provided the ﬁrst clinically rele-
vant evidence supporting a role for TRIM22 as an anti-
HIV-1 eﬀector in vivo. They showed that expression of6 Molecular Biology International
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Figure 3: Possible mechanisms of TRIM22 antiviral functions. Based on current reports, TRIM22 can inhibit viral replication through
nuclear-associated eﬀects such as inhibiting viral transcription. Although not investigated to date, RNA export and translation are also
potential targets of TRIM22. Given its E3 ligase activity, TRIM22 may posttranslationally modify host or viral proteins that are required for
viral assembly and/or budding. Posttranslational modiﬁcations occur when an E1 activating enzyme (E1), E2 conjugating enzyme (E2), and
E3 ligase protein (E3) work together to transfer ubiquitin or ubiquitin-like molecules to a target protein. These modiﬁcations could target
the protein for proteasomal degradation or alter its subcellular localization or ability to interact with other proteins or DNA.
TRIM22 in peripheral blood mononuclear cells (PBMCs)
of HIV-1-infected individuals was signiﬁcantly increased in
patients after HIV-1 infection. Importantly, infected patients
expressinghigherTRIM22levelsexhibitedsigniﬁcantlylower
viral loads and signiﬁcantly higher CD4+ T-cell counts
[26]. These ﬁndings are quite signiﬁcant, as this suggests
that TRIM22 has a potential eﬀect on the severity and/or
progression of HIV-1 infection. Additional research on the
role of TRIM22 during primary infection will be important
to provide a greater understanding of the eﬀects TRIM22
may have on HIV-1 replication in vivo.
The antiviral activities of TRIM22 are not limited to
HIV-1. In 2009, Eldin et al. identiﬁed TRIM22 as a potent
inhibitorofencephalomyocarditisvirus(EMCV)replication.
TRIM22 was shown to interact with the EMCV 3C protease
via the C-terminal domain of TRIM22, and expression of
TRIM22 corresponded with increased ubiquitination of the
3C protease (Figure 3). 3C protease is essential for successful
viral replication and has several roles, including processing
of the viral polyprotein and inhibition of the host immune
defences [11]. There are also reports that TRIM22 may
play an important role in protecting the liver from viral
pathogens. In 2009, Gao et al. reported that TRIM22 is
highly upregulated in response to type I or II IFN in the
hepatocellular carcinoma cell line HepG2. Cotransfection
of plasmids encoding TRIM22 and replication-competent
hepatitis B virus (HBV) inhibited the accumulation of HBV
antigensinthesupernatantsofcellsandsigniﬁcantlyreduced
levels of intracellular HBV RNA and DNA replication
intermediates. Similar results were observed in the sera
of mice during codelivery of plasmids to mouse livers,
showing that TRIM22 can restrict HBV infection in an
in vivo system. Using a luciferase reporter plasmid, they
showed that TRIM22 downregulates expression from the
HBV core promoter (Figure 3). This mechanism of action
was dependent on the nuclear localization of TRIM22
and its E3 ubiquitin ligase activity [13]. Although there
is no direct evidence for a protective role of TRIM22
against HBV in primates, TRIM22 expression is signiﬁcantly
upregulated during clearance of HBV in chimpanzees [51].
Moreover, TRIM22 expression is signiﬁcantly upregulated
during clearance of hepatitis C virus (HCV) in chimpanzees
[52]. These ﬁndings are paralleled in human infections, as
TRIM22 is signiﬁcantly upregulated in cirrhotic liver from
HCV patients and patients with mild chronic HCV infection
and no ﬁbrosis [53]. Further research is needed to assess the
role of TRIM22 in inhibiting HBV and HCV in vivo.
In further support of the notion that TRIM22 is
involved in the host antiviral response, TRIM22 expression
is modulated in response to several other viruses and viral
antigens (Table 2). TRIM22 expression is upregulated in
response to infection with rubella virus [54] and Epstein-
Barr virus (EBV) [55] and downregulated during infec-
tion with human papillomavirus type 31 [56]. A couple
intriguing reports elude to the possibility that TRIM22 may
also contribute to viral latency. Exogenous expression of
TRIM22 signiﬁcantly upregulates expression of the EBV
latent membrane protein 1 (LMP-1) [55]. LMP-1 is required
for latency during EBV infection and appears to induce an
antiviral state by upregulating expression of several ISGs via
an IFN- and STAT1-independent mechanism. The Kaposi’s
sarcoma-associated herpesvirus (KSHV) latency-associated
nuclear antigen (LANA) also activates several ISGs including
TRIM22, which was shown to be upregulated by LANA both
in culture and in tissues from KSHV lesions. LANA also
repressed transcription from the HIV-1 LTR, an NFκBc o n -
sensus sequence, and the SV40 promoter [57]. Furthermore,
TRIM22 is expressed in resting T cells, which are known
reservoirsoflatentHIV-1,andisstronglyrepressedduringT-
cell activation [47]. Although much more research is needed
to directly implicate TRIM22 in viral latency, it is tempting
to hypothesize that TRIM22 contributes to viral latency.
4.3. Other Functions of TRIM22. Several reports in the litera-
ture suggest that TRIM22 may have a role in other biological
processes, such as cell diﬀerentiation and proliferation. OneMolecular Biology International 7
Table 2: Summary of factors that alter TRIM22 expression.
Stimulation Change Tissue Reference
Cytokines
IFN-α increase CEM, Jurkat, and THP-1 cells [26]
IFN-α increase H9 cells [47]
IFN-α increase HepG2 cells [13]
IFN-α increase Primary MDM [24]
IFN-α increase U937 [25]
IFN-α increase U-937-4 cells [46]
IFN-α/β increase Daudi, and HeLa cells [45]
IFN-β increase HOS cells [14]
IFN-γ increase HeLa cells [30, 45]
IFN-γ increase HepG2 cells [13, 48, 49]
IFN-γ increase MCF7 cells [30]
IL-1-β increase Coronary artery endothelium [58]
IL-2 increase CD4+, CD8+, NK cells [50]
IL-15 increase CD4+, CD8+, NK cells [50]
Progesterone increase ABC28, and T47D cells [30]
TNF-α increase Coronary artery endothelium [58]
Antigens/Infections
EBV infection1 increase BL41-EBV cells1 [55]
EBV LMP-1 increase DG75 cells [55]
Hepatitis B virus infection2 increase Liver tissue2 [51]
Hepatitis C virus infection2 increase Liver tissue2 [52]
Hepatitis C virus infection increase Liver tissue [53]
HIV-1 infection increase Immature DC [55]
HIV-1 infection increase Primary MDM [24]
HIV-1 infection increase Primary PBMCs [26]
HIV-1 Tat increase Immature DC [55]
HPV infection decrease Human keratinocytes [56]
KSHV infection increase KSHV lesion [57]
KSHV LANA increase BJAB cells [57]
LPS increase Primary MDM [24]
Rubella virus infection increase ECV304 cells [54]
Activation/Diﬀerentiation/Cell Cycle
1α,25-dihydroxyvitamine D33 increase Primary MDM [24]
Anti-CD2 increase Primary T cells [47]
Anti-CD2/CD28 decrease Primary T cells [47]
Anti-CD2/CD28/CD3 decrease CD4+, CD8+, NK cells4 [50]
All-trans retinoic acid increase HL60 and NB4 cells [46]
All-trans retinoic acid increase Primary MDM [24]
p53 increase K562 and U-937-4 cells5 [46]
p73 increase U-937-4 cells [46]
Pioglitazone increase Primary MDM [24]
UV-irradiation6 increase MCF-7 cells [46]
Disease
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Table 2: Continued.
Stimulation Change Tissue Reference
Wilms tumor decrease Tumor tissue [60, 61]
1BL41 cells that are latently infected with EBV.
2From infected chimpanzees.
3Hormonally active form of Vitamin D.
4Only reached signiﬁcance in CD8+ cells.
5Cells lack endogenous p53 but stably express a plasmid encoding p53 under control of a temperature-sensitive promoter. Cells were grown at the permissive
temperature (32◦C) to induce p53 expression.
6UV-irradiation induces p53 expression.
group showed that the expression of TRIM22 is directly
activated by p53 in myeloid cells via a functional p53-
response element in intron 1 of the TRIM22 gene [46].
They also showed that the p53-family member p73 can bind
to this response element and activate TRIM22 expression
[46]. Since p73 has been linked to the diﬀerentiation of
leukemic cells [62], the authors speculated that TRIM22 may
be involved in cell diﬀerentiation. Another group reported
that TRIM22 expression is signiﬁcantly upregulated during
diﬀerentiation of the promyelocytic cell line NB4 [63]. They
also showed that TRIM22 expression is high in monocytes
and early granulocytes but decreases in the lymphocyte and
lategranulocytepopulationsandisundetectableinerythroid
cells [63]. Obad et al. (2004) provided the ﬁrst direct
evidence supporting an antiproliferative role for TRIM22 by
showingthatoverexpressionofTRIM22inthepromonocytic
cell line U937 resulted in decreased clonogenic growth [46].
An inverse correlation between TRIM22 expression and cell
diﬀerentiation has also been reported, showing that TRIM22
ishighlyexpressedinhumanimmatureCD34+ bonemarrow
progenitor cells, but declines in mature populations [63].
Despite the correlations of TRIM22 expression levels with
cell diﬀerentiation and proliferation, the evidence lacks key
experiments such as loss-of-function studies (i.e., TRIM22
knockdown) to conclusively implicate TRIM22 as a key
player in any of these processes.
A couple of reports have associated TRIM22 with human
disease. Downregulation of TRIM22 expression is associated
with progression, relapse and increased mortality in cases
of Wilms tumor [60, 61]. Although TRIM22 is a p53-
responsive gene and may promote cell-cycle arrest [46],
its role in tumour development and progression, including
Wilms tumor, is yet to be determined. The involvement of
TRIM proteins in cancer is not unprecedented. TRIM13, 24,
and 29, which are also involved in p53 regulation, have also
been implicated as important regulators for carcinogenesis.
Moreover, TRIM19/PML may act as a tumour suppressor
protein (reviewed in [4]). TRIM22 expression is also down-
regulated in CD4+ T cells from patients with active systemic
lupus erythematosus (SLE) [59]. Although it is also unclear
what role TRIM22 plays in this disease, it is notable that
several other TRIM proteins, including TRIM 21, 25, 56, and
68, have been linked to SLE and other autoimmune diseases
[5]. It will be interesting to learn more about the role (if any)
TRIM22 plays in these and other human diseases.
Although it is clear that TRIM22 is an exciting and
dynamic protein, it appears that we have only begun to
understand its role in cellular biology and antiviral immu-
nity. A rich evolutionary history, together with its potential
involvement in numerous biological processes, suggests that
TRIM22 is an important and multifarious protein. Despite
its importance, the function of TRIM22 remains poorly
understood,andanumberofissueswillneedtobeaddressed
in future research. One discrepancy that needs clariﬁcation
is the disparate observations and contradictory reports
surrounding TRIM22 subcellular localization. In particular,
we need to understand why TRIM22 localization is so
heterogeneous, as this may provide useful insight into its
biological function. Another priority will be to consolidate
previous reports on the antiviral mechanism of TRIM22.
In the case of HIV-1, it will be important to determine the
stage(s) of the virus lifecycle that TRIM22 targets. In this
regard, future studies that identify the host and/or virus
targets of TRIM22 will be extremely useful. In addition, it
willbeinterestingtodiscoverifTRIM22hasantiviralactivity
against additional viruses, and to determine the role it plays
inothernonviraldiseases.Overall,itsbreadthofinvolvement
in antiviral immunity, combined with the range of possible
mechanisms by which TRIM22 acts, presents a number of
excitingresearchopportunities.FutureworkonTRIM22will
helpusunderstandthisimportantplayerinthehostantiviral
response and contribute to our knowledge of host-pathogen
interactions.
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